Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04521686
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-05
First Post:
2020-08-13
Brief Title:
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Any Solid Tumor |
| Cholangiocarcinoma |
| Chondrosarcoma |
| Glioma |
Keywords:
| Name | View |
|---|---|
| IDH1 | View |
| CNS tumor | View |
| Cholangiocarcinoma | View |
| Chondrosarcoma | View |
| Glioma | View |
| Glioblastoma | View |
| Solid tumor | View |
| Primary CNS tumor | View |
| Colon cancer | View |
| Cancer of the Colon | View |
| Colon Neoplasms | View |
| Colonic Cancer | View |
| Neoplasms Colonic | View |
| Malignant tumor of Breast | View |
| Mammary Cancer | View |
| Mammary Carcinoma Human | View |
| Mammary Neoplasm Human | View |
| Neoplasms Breast | View |
| Tumors Breast | View |
| Human Mammary Carcinoma | View |
| Malignant Neoplasm of Breast | View |
| Breast Carcinoma | View |
| Breast Tumors | View |
| Cancer of the Breast | View |
| Breast Neoplasms | View |
| Breast Cancer | View |
| Thyroid cancer | View |
| Prostate cancer | View |
| Melanoma | View |
| IDH1 R132 | View |